Eckert & Ziegler Strahlen- und Medizintechnik AG

Regulatory Filings • Jan 4, 2007

News Details

Corporate | 4 January 2007 09:32

Eckert & Ziegler: Another large-scale order in Venezuela

ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Alliance/Contract

Corporate news transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Berlin, 4 January 2007. Following a previous large-scale order, the
Venezuelan Health Ministry has ordered additional innovative cancer
radiation systems from Eckert & Ziegler AG (ISIN DE0005659700) at the start
of 2007 to supply six more of the country's clinics. These are MultiSource®
tumor radiation systems, which feature especially low operating costs
thanks to their cobalt radiation sources.

In order to equip its network of cancer treatment centers, Venezuela had
already ordered tumor radiation systems worth several million USD from the
Berlin-based medical equipment specialist last year, via the latter's
distribution partners Philips and Servicios Radioma. This new order, which
is scheduled to be filled in 2007, is worth around 1.6 million USD (1.2
million EUR).

According to Dr. Edgar Löffler, the member of the Executive Board in charge
of the therapy segment and the managing director of the relevant subsidiary
Eckert & Ziegler BEBIG GmbH, 'This order demonstrates once again that the
product family we launched a mere two years ago is now successfully
established on the international market and that the innovative approach of
using long-life radiation sources is recognized and rewarded. It reflects
not only the fact that MultiSource® allows users free choice in the type of
radioisotope, but also a number of new features and the planning system'.

Cancer treatment with MultiSource®:
Tumor radiation systems for treating cancer (the technical term is
'afterloaders') insert a small radioactive source inside the affected
organ, such as the uterus, in order to radiate the cancerous tissue from
inside the body. Thanks to the spatial proximity between the radioactive
source and the diseased tissue, a high dose can be focused directly on the
tumor while the adjacent healthy organs can be largely spared. To do so, an
empty catheter is first inserted. After checking on its position by e.g.
X-ray or ultrasound, medical personnel can leave the treatment room. A
radioactive source is then 'afterloaded' – via an electronic control system
– into the catheter. Following the radiation treatment, the source is
removed by the same procedure. The advantages of afterloading are that the
tumor receives a high radioactive dose while the tissue is largely spared.
Moreover, medical personnel are no longer exposed to possible radiation
themselves. Afterloading is a well-established technique for treating
tumors in the uterus, breast, esophagus, lungs, and prostate.

Your contact:
Eckert & Ziegler AG
Karolin Riehle, Investor Relations, Robert-Rössle-Str. 10, D-13125 Berlin
Phone: +49 (0) 30 / 94 10 84-138; Fax -112; e-mail: karolin.riehle@ezag.de,
www.ezag.de

DGAP 04.01.2007

Language: English
Issuer: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin Deutschland
Phone: +49 (0)30 941 084-0
Fax: +49 (0)30 941 084-112
E-mail: karolin.riehle@ezag.de
WWW: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices:
Listed: Geregelter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin-Bremen, München, Hamburg, Düsseldorf

End of News DGAP News-Service

---